CRC
CRSP icon

Curi RMB Capital’s CRISPR Therapeutics CRSP Stock Holding History

Curi RMB Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.22M Buy
59,032
+9,326
+19% +$492K 0.05% 289
2026
Q1 		$2.36M Sell
49,706
-885
-2% -$46.7K 0.04% 307
2025
Q4 		$2.65M Sell
50,591
-892
-2% -$53.4K 0.05% 296
2025
Q3 		$3.34M Buy
51,483
+66
+0.1% +$3.79K 0.06% 261
2025
Q2 		$2.5M Buy
51,417
+4,187
+9% +$162K 0.05% 294
2025
Q1 		$1.61M Sell
47,230
-1,831
-4% -$77.6K 0.04% 291
2024
Q4 		$1.93M Buy
49,061
+2,346
+5% +$111K 0.04% 270
2024
Q3 		$2.19M Buy
46,715
+7,597
+19% +$385K 0.05% 261
2024
Q2 		$2.11M Buy
39,118
+4,804
+14% +$278K 0.05% 259
2024
Q1 		$2.34M Buy
34,314
+2,804
+9% +$201K 0.05% 254
2023
Q4 		$1.97M Buy
31,510
+92
+0.3% +$5.09K 0.06% 233
2023
Q3 		$1.43M Sell
31,418
-152
-0.5% -$7.85K 0.05% 252
2023
Q2 		$1.77M Hold
31,570
– – 0.06% 236
2023
Q1 		$1.43M Buy
31,570
+4,835
+18% +$235K 0.05% 251
2022
Q4 		$1.09M Sell
26,735
-9,496
-26% -$504K 0.04% 274
2022
Q3 		$2.37M Hold
36,231
– – 0.09% 209
2022
Q2 		$2.2M Sell
36,231
-3,795
-9% -$223K 0.08% 210
2022
Q1 		$2.51M Buy
40,026
+6,629
+20% +$416K 0.08% 177
2021
Q4 		$2.53M Buy
33,397
+11,148
+50% +$974K 0.08% 179
2021
Q3 		$2.49M Buy
22,249
+6
+0% +$754 0.08% 185
2021
Q2 		$3.6M Buy
22,243
+10,981
+98% +$1.34M 0.12% 154
2021
Q1 		$1.37M Buy
11,262
+8,362
+288% +$1.26M 0.05% 225
2020
Q4 		$444K Hold
2,900
– – 0.02% 442
2020
Q3 		$243K Hold
2,900
– – 0.01% 531
2020
Q2 		$213K Buy
+2,900
New +$170K 0.01% 536

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Curi RMB Capital's CRSP Position: Q2 2026 in Review

Curi RMB Capital increased its CRISPR Therapeutics (CRSP) stake by 19% in Q2 2026, buying an estimated $492K and bringing the position to 59,032 shares worth $3.22M. The position accounts for 0.05% of the portfolio, ranked #289.

Curi RMB Capital first reported a position in CRSP in Q2 2020 and has held it in 25 quarters since. The position peaked at $3.6M in Q2 2021. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Curi RMB Capital held 59,032 shares of CRISPR Therapeutics worth $3.22M as of Q2 2026.
  • Curi RMB Capital bought 9,326 CRISPR Therapeutics shares in Q2 2026, an estimated $492K.
  • CRISPR Therapeutics made up 0.05% of Curi RMB Capital's portfolio in Q2 2026, its #289 holding.
  • Curi RMB Capital first reported a position in CRISPR Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Curi RMB Capital's CRISPR Therapeutics position peaked at $3.6M in Q2 2021.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Curi RMB Capital's 13F filing for Q2 2026, filed 14 Aug 2026.